ÂÜÀòÂÒÂ×

Adrienne Farid is Century’s Chief Development Officer. She joined Century from Celgene, where she was Corporate Vice President, Project Leadership and Business Operations in Research & Early Development. Her group ran early development teams, in the past few years filing >20 Investigational New Drug (IND)/Clinical Trial Applications (CTAs) and progressing numerous Phase 1/2 assets in hematology, oncology, and inflammation/immunology. Adrienne was co-lead of the global Liso-cel development team with Juno Therapeutics from 2015-2017, and as part of collaboration governance, she was instrumental in contributing to Celgene’s cell therapy strategies. She led Celgene’s integration of Juno Therapeutics in 2018. Earlier, Adrienne led global development teams, including Pomalyst® in relapsed/refractory multiple myeloma through registration. At Roche for 15 years, she advanced through technical and global development leadership. She began her career at SmithKline Beecham. Adrienne received her Ph.D. in Chemistry from Columbia University, followed by postdoctoral studies at California Institute of Technology.